Año: 2014
Journal Impact Factor (JIF): 4.590
Categoría | Edición | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|---|
OBSTETRICS & GYNECOLOGY | SCIE | 4/79 | Q1 | T1 | D1 |
REPRODUCTIVE BIOLOGY | SCIE | 2/30 | Q1 | T1 | D1 |
Año: 2017
Journal Citation Indicator (JCI): 1,920
Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
---|---|---|---|---|---|
OBSTETRICS & GYNECOLOGY | 6/115 | Q1 | T1 | D1 | 95,22 |
REPRODUCTIVE BIOLOGY | 3/31 | Q1 | T1 | D1 | 91,94 |
Año:
2014
CiteScore:
7,600
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Obstetrics and Gynecology | 4/160 | Q1 | T1 | D1 |
Reproductive Medicine | 3/58 | Q1 | T1 | D1 |
General Medicine | 386/3264 | Q1 | T1 | D2 |
SJR año:
2014
Factor de Impacto:
1,983
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Obstetrics and Gynecology | 7/191 | Q1 | T1 | D1 |
Reproductive Medicine | 4/77 | Q1 | T1 | D1 |
Agencia | Código de Proyecto |
---|---|
Andromed | - |
Angelini | - |
Ardana | - |
Child health | - |
COGI | - |
CVON | - |
Euroscreen | - |
Ferring Pharmaceuticals | - |
Merck | - |
Merck Serono | - |
MSD | - |
OvaScience | - |
Roche | - |
Watson Laboratories | - |
# | Autor | Afiliación |
---|---|---|
1 | Ferring Pharmaceuticals AS (Switzerland) | |
2 | Nyboe Andersen, Anders | Rigshospitalet (Denmark) |
3 | Fernández-Sánchez, Manuel | IVI Sevilla (Spain) |
4 | Visnova, Hana | Sin datos () |
5 | Bosch, Ernesto | IVI Valencia (Spain) |
6 | García-Velasco, Juan Antonio | IVI-Madrid (Spain) |
7 | Barri, Pedro | Gynecology & Reproduction (Spain) |
8 | De Sutter, Petra | University Hospital of Ghent (Belgium) |
9 | Klein, Bjarke M. | Ferring Pharmaceuticals AS (Switzerland) |
10 | Fauser, Bart C.J.M. | University Medical Center Utrecht (Netherlands) |